Novartis H1N1 Vaccine in Pregnant Women
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00992719 |
Recruitment Status
:
Completed
First Posted
: October 9, 2009
Results First Posted
: March 5, 2012
Last Update Posted
: August 7, 2013
|
Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Tracking Information | |||
---|---|---|---|
First Submitted Date ICMJE | October 8, 2009 | ||
First Posted Date ICMJE | October 9, 2009 | ||
Results First Submitted Date | January 19, 2012 | ||
Results First Posted Date | March 5, 2012 | ||
Last Update Posted Date | August 7, 2013 | ||
Study Start Date ICMJE | November 2009 | ||
Actual Primary Completion Date | February 2011 (Final data collection date for primary outcome measure) | ||
Current Primary Outcome Measures ICMJE |
|
||
Original Primary Outcome Measures ICMJE |
|
||
Change History | Complete list of historical versions of study NCT00992719 on ClinicalTrials.gov Archive Site | ||
Current Secondary Outcome Measures ICMJE |
|
||
Original Secondary Outcome Measures ICMJE |
|
||
Current Other Outcome Measures ICMJE | Not Provided | ||
Original Other Outcome Measures ICMJE | Not Provided | ||
Descriptive Information | |||
Brief Title ICMJE | Novartis H1N1 Vaccine in Pregnant Women | ||
Official Title ICMJE | A Phase II Study In Pregnant Women to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Inactivated Influenza Vaccine Administered at Two Dose Levels | ||
Brief Summary | The purpose of this study is to evaluate the safety of a 2009 H1N1 influenza vaccine in pregnant women and to determine how their body reacts to different strengths of the vaccine. Two strengths of the H1N1 influenza vaccine will be tested. Since it is not known if the response to the vaccine in pregnant women is the same or different than in non-pregnant women, the study also includes a group of women who are not pregnant for comparison. Participants include 200 pregnant women and 100 non-pregnant women ages 18-39. Study procedures include physical exams, several blood samples and maintaining a memory aid to document daily temperature and side effects for 8 days following vaccination. Participants will be involved in study related procedures for about 6 months. | ||
Detailed Description | Recently, a novel swine-origin influenza A/H1N1 virus was identified as a significant cause of febrile respiratory illnesses in Mexico and the United States. It rapidly spread to many countries around the world, prompting the World Health Organization to declare a pandemic on June 11, 2009. Pregnant women are at an increased risk for serious consequences of influenza infection. A 15 microgram (mcg) dose of unadjuvanted inactivated H1N1 vaccine is recommended for healthy adults and recent preliminary data indicates this dose is likely to be protective for pregnant women. However, a higher dose of an unadjuvanted, inactivated influenza H1N1 vaccine may be necessary to confer optimal protection to this at risk population. This protocol will explore the antibody response following vaccination of pregnant women at 2 different dose levels (15 mcg and 30 mcg) and a non-pregnant control group receiving a 15 mcg dose. Antibody responses will be assessed at 21 days and 180 days post vaccination. For pregnant women, maternal and cord blood will be collected to determine the level of H1N1 antibodies transferred to the baby. An optimal immune response in pregnant women would impact transplacental transport of protective antibodies which is important since vaccines are not available for infants younger than six months, another at risk population for severe H1N1 disease. Sustained immunity for at least 6 months post-vaccination would impart benefit not only to the woman herself but also decrease a primary exposure risk (infected mother) for the newborn infant. Furthermore, a systematic evaluation of the kinetics of maternally transferred antibodies to 2009 H1N1 influenza virus will help improve and develop strategies to protect infants from influenza. This is an open label, Phase II study in pregnant and non-pregnant women, aged 18-39 years old designed to investigate the safety, reactogenicity, and immunogenicity of an inactivated influenza H1N1 virus vaccine. Pregnant women will be randomized into 2 groups (100 per dose group) to receive intramuscular (IM) inactivated influenza H1N1 vaccine at 15 mcg (Group 1) or 30 mcg (Group 2). A non-pregnant control group of 100 subjects will receive IM inactivated influenza H1N1 vaccine at 15 mcg (Group 3). Following immunization, safety will be measured by assessment of adverse events (AEs) through 21 days post vaccination (serious AEs and new-onset chronic medical conditions monthly through 6 months post vaccination (Day 180). Reactogenicity to the vaccine will be assessed for 8 days following vaccination (Day 0-7). Immunogenicity testing will include hemagglutination inhibition assay (HAI) and neutralizing antibody testing on serum obtained on Days 0, 21, and 180. For the pregnant groups, HAI antibody testing will also be performed on serum from the participant at delivery, on serum from cord blood collected at delivery and, when possible, on serum samples collected from the participant at day 180 and from the infant at 6 weeks, four months, or six months after delivery. The primary safety objective is to assess the safety of unadjuvanted, inactivated H1N1 influenza vaccine in pregnant women when administered at the 15 mcg or 30 mcg dose. The primary immunogenicity objective is to assess the antibody response to unadjuvanted, inactivated H1N1 influenza vaccine in pregnant women when administered at the 15 mcg or 30 mcg dose. The secondary objective for pregnant women is to assess the efficiency of placental transport of maternal influenza antigen specific antibodies to the neonate. | ||
Study Type ICMJE | Interventional | ||
Study Phase | Phase 2 | ||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Prevention |
||
Condition ICMJE | Influenza | ||
Intervention ICMJE | Biological: Inactivated H1N1 Vaccine
H1N1 vaccine [Influenza A (H1N1) 2009 Monovalent Vaccine] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm. |
||
Study Arms |
|
||
Publications * | Not Provided | ||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||
Recruitment Information | |||
Recruitment Status ICMJE | Completed | ||
Actual Enrollment ICMJE |
84 | ||
Original Estimated Enrollment ICMJE |
300 | ||
Actual Study Completion Date | February 2011 | ||
Actual Primary Completion Date | February 2011 (Final data collection date for primary outcome measure) | ||
Eligibility Criteria ICMJE | Inclusion Criteria: Pregnant women:
Non-pregnant women:
Exclusion Criteria: Pregnant women:
Non-pregnant women:
|
||
Sex/Gender |
|
||
Ages | 18 Years to 39 Years (Adult) | ||
Accepts Healthy Volunteers | Yes | ||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||
Listed Location Countries ICMJE | United States | ||
Removed Location Countries | |||
Administrative Information | |||
NCT Number ICMJE | NCT00992719 | ||
Other Study ID Numbers ICMJE | 09-0072 N01AI80057C |
||
Has Data Monitoring Committee | Not Provided | ||
U.S. FDA-regulated Product | Not Provided | ||
IPD Sharing Statement | Not Provided | ||
Responsible Party | National Institute of Allergy and Infectious Diseases (NIAID) | ||
Study Sponsor ICMJE | National Institute of Allergy and Infectious Diseases (NIAID) | ||
Collaborators ICMJE | Not Provided | ||
Investigators ICMJE | Not Provided | ||
PRS Account | National Institute of Allergy and Infectious Diseases (NIAID) | ||
Verification Date | July 2010 | ||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |